Sarepta Therapeutics Inc. (Nasdaq: SRPT) reported positive results from a Phase 1/2 study of golodirsen to treat patients with Duchenne muscular dystrophy sending the stock price soaring $5.65 to close at $46.73.
Sarepta Therapeutics reports positive study data
September 06, 2017 at 18:33 PM EDT
